You are about to leave www.astellas.com and enter a third-party website. Astellas is not responsible for the content or services on the third-party website.
Would you like to continue?
View detailed Astellas share data information by selecting 'learn more’.
Astellas has reached more than 172 million patients in 103 countries and areas around the world with our products. Our on-market portfolio includes transformative therapies in oncology, ophthalmology, urology, immunology, and women's health.
Through our research and development programs, Astellas is pioneering new healthcare solutions in disease areas with high unmet medical need.
For institutional investors and securities analysts
For Individual investors or inquiry for Astellas’ stock (Japanese only)
Please visit the IR Library to access key documents such as the Integrated Report, shareholder meeting materials, and more.
Please visit the Financial Results Library for all quarterly earnings materials.
See find information on all upcoming and past events in the IR Library.
Astellas’ Corporate Strategic Plan (CSP) is a set of guiding principles and strategies that enables us to continue our journey to realize our Vision of turning innovative science into VALUE for patients.
